We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Printable POC SARS-CoV-2 Antibody Test for COVID-19 Could Produce Results in Real Time

By HospiMedica International staff writers
Posted on 01 Dec 2020
Print article
Image: Printable POC SARS-CoV-2 Antibody Test for COVID-19 Could Produce Results in Real Time (Photo courtesy of Wyss Institute at Harvard University)
Image: Printable POC SARS-CoV-2 Antibody Test for COVID-19 Could Produce Results in Real Time (Photo courtesy of Wyss Institute at Harvard University)
A low-cost electrochemical technology for multiplexed biomarker detection could facilitate global serological testing for SARS-CoV-2 infections, and help trace immunity in individuals over time.

The Wyss Institute for Biologically Inspired Engineering at Harvard University (Boston, MA, USA) has licensed its eRapid technology to The iQ Group Global (Sydney, Australia) for COVID-19 diagnostic applications.

The eRapid technology is a low-cost, affinity-based electrochemical sensing platform that can multiplex simultaneous detection and quantification of a broad range of biomarkers, including proteins, antibodies, RNA, and small molecules with high sensitivity and selectivity in small quantities of complex biological fluids, such as blood or saliva. The eRapid technology is based on a novel, antifouling nanocomposite coating to which SARS-CoV-2-specific antibodies are attached that capture viral proteins or RNA, or antibodies produced by infected individuals in response to the virus. Upon chemically detecting any one of these virus-specific molecules, the eRapid platform generates an electrical signal, and the strength of that signal correlates directly with the levels of target molecules present in the sample. The antifouling coating enables eRapid technology to provide low cost electrochemical sensors with higher sensitivity and specificity, while the multiplexed nature of the devices allows them to validate diagnosis by quantifying the levels of multiple different viral components and host response molecules. As the coating also allows these devices to be re-used multiple times with consistent specificity and sensitivity, the costs of diagnostic assays can be reduced even further.

The iQ Group Global will integrate the Wyss' eRapid technology with its biosensor platform. A key component of the platform is the company's proprietary Organic Thin Film Transistor technology, which is able to significantly enhance electrical signals such as the ones generated by eRapid, and allow them to be read out in a smart device to provide diagnostic answers in real time. The idea is to coat the sensors designed to detect IgM and/or IgG antibodies, which indicate a person’s current or previous exposure to the SARS-CoV-2 virus and, thus, a potential infection with COVID-19. This could lead to the creation of a chewing-gum-sized diagnostic ‘strip’ that can be used for COVID-19 testing at point of care, with the ability to be printed at scale at a low cost, and produce real-time results.

"Our eRapid technology offers the possibility of developing inexpensive diagnostic tests that have the potential to accurately determine the presence of infection, the stage of the infection, and the patient's response to the virus all simultaneously," said the Wyss' Founding Director Donald Ingber, M.D., Ph.D.

"eRapid's features and capabilities would make it an effective tool for easily tracing active immunity in infected individuals and those that recovered from COVID-19 to help determine their basis for resistance. Such a versatile platform that helps us better understand how the disease develops, persists, and can be controlled could be an invaluable asset in the fight against the pandemic," said Wyss Senior Staff Scientist Pawan Jolly, Ph.D.

"Non-invasive, low cost and scalable SARS-Cov-2 antibody testing is urgently needed to estimate the incidence and prevalence of SARS-Cov-2 infection at the general population level. We intend to focus on placing this SARS-Cov 2-test as a potential companion diagnostic to the vaccination programs globally. Given the analytical characteristics of the biosensor and its stage of development, the combined technologies position us excellently to develop a more accurate, sensitive and real-time SARS-CoV-2 test for diagnostic, point-of-care testing, and pre-vaccination screening to meet this urgent global need," said Dr. George Syrmalis, Group CEO of The iQ Group Global.

Related Links:
Wyss Institute for Biologically Inspired Engineering at Harvard University
The iQ Group Global


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Flocked Fiber Swabs
Puritan® patented HydraFlock®
New
Diagnosis Display System
C1216W
New
Fixed Height Patient Trolley
GT1501

Print article
Radcal

Channels

Critical Care

view channel
mage: The electroceutical epidermal patch is designed to inhibit bacterial growth (Photo courtesy of Saehyun Kim/University of Chicago)

Cutting-Edge Bioelectronic Device Offers Drug-Free Approach to Managing Bacterial Infections

Antibiotic-resistant infections pose an increasing threat to patient safety and healthcare systems worldwide. Recent estimates indicate that drug-resistant infections may rise by 70% by 2050, highlighting... Read more

Surgical Techniques

view channel
Image: Conceptual schematic showing microgrippers (µ-grippers) operating as biopsy tools in the upper urinary tract (Photo courtesy of Wangqu Liu, Yan Wan/Gracias Lab, Johns Hopkins University)

Microgrippers For Miniature Biopsies to Create New Cancer Diagnostic Screening Paradigm

The standard diagnosis of upper urinary tract cancers typically involves the removal of suspicious tissue using forceps, a procedure that is technically challenging and samples only a single region of the organ.... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more